Alzheimer’s Association International Conference (AAIC®)

Hugo will also present two abstracts that address a growing priority in neuroscience R&D: ensuring the right treatment reaches the right patient at the right time. His team’s research highlights how model-informed strategies can:

• Account for patient variability (e.g., APOE genotype, disease stage)
• Enable smarter, more targeted clinical trial designs
• Reduce trial failure and accelerate development timelines
• Support early intervention without increasing patient risk

These insights are shaping the future of personalized Alzheimer’s treatment.